During the last ~10 years, a generation of molecules with agonism at the glucagon-like peptide-1 (GLP-1) receptor have emerged as promising tools in the pharmacotherapy of obesity (106–108). This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.